AR056838A1 - Derivados de 1,2,5-tiadiazol - Google Patents

Derivados de 1,2,5-tiadiazol

Info

Publication number
AR056838A1
AR056838A1 ARP060105392A ARP060105392A AR056838A1 AR 056838 A1 AR056838 A1 AR 056838A1 AR P060105392 A ARP060105392 A AR P060105392A AR P060105392 A ARP060105392 A AR P060105392A AR 056838 A1 AR056838 A1 AR 056838A1
Authority
AR
Argentina
Prior art keywords
amino
alkoxy
heterocyclyl
cycloalkyl
aryl
Prior art date
Application number
ARP060105392A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37950917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056838(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR056838A1 publication Critical patent/AR056838A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

REIVINDICACIoN 1.- Un compuesto de la Formula (I) en donde: Q, combinado junto con los átomos de carbono con los que está unido, forma un anillo carbocíclico o heterocíclico de 5 a 8 miembros, aromático, o no aromático parcial o completamente saturado; R1es hidrogeno, -C(O)R6, -C(O)NR7R8, o -C(O)OR9, en donde: R6 y R7 son, independientemente uno del otro, hidrogeno, cicloalquilo, arilo, heterociclilo, aralquilo, heteroaralquilo, o alquilo opcionalmente sustituido por 1 a 4 sustituyentes seleccionados a partir del grupo que consiste en halogeno, cicloalquilo, cicloalcoxilo, alcoxilo, alquiloxi-alcoxilo, amino, alquilamino, dialquil-amino, arilo, ariloxilo, y heterociclilo; R8 y R9 son, independientemente uno del otro, cicloalquilo, arilo, heterociclilo, aralquilo, heteroaralquilo, o alquilo opcionalmente sustituido por 1 a 4 sustituyentes seleccionados a partir del grupo que consiste en halogeno, cicloalquilo, cicloalcoxilo, alcoxilo, alquiloxi-alcoxilo, amino, alquil-amino, dialquil-amino, arilo, ariloxilo, y heterociclilo; R2, R3, R4 y R5 son, independientemente unos de otros, hidrogeno, hidroxilo, halogeno, ciano, nitro, alcoxilo, tioalquilo, tionoalquilo, sulfonilo, carboxilo libre o esterificado, carbamoílo, sulfamoílo, amino opcionalmente sustituido, cicloalquilo, arilo, heterociclilo, alquenilo, alquinilo, o alquilo (de 1 a 8 átomos de carbono) opcionalmente sustituido por 1 a 4 sustituyentes seleccionados a partir del grupo que consiste en halogeno, hidroxilo, cicloalquilo, cicloalcoxilo, acilo, aciloxilo, alcoxilo, alquiloxi-alcoxilo, amino, alquil-amino, dialquil-amino, acil-amino, carbamoílo, tiol, rioalquilo, tionoalquilo, sulfonilo, sulfonamido, sulfamoílo, nitro, ciano, carboxilo libre o esterificado, arilo, ariloxílo, tioarílo, alquenilo, alquinilo, aralcoxilo, heteroaralcoxilo, heterociclilo, y heterocicliloxilo; o R2 y R3 combinados son alquileno que, junto con los átomos del anillo con los que están unidos, forman un anillo fusionado de 3 a 7 miembros; o R2 y R3 combinados son alquileno que, junto con el átomo de carbono con el que están unidos, forman un anillo espirocíclico de 3 a 7 miembros; o una sal farmacéuticamente aceptable del mismo.
ARP060105392A 2005-12-08 2006-12-06 Derivados de 1,2,5-tiadiazol AR056838A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74857305P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
AR056838A1 true AR056838A1 (es) 2007-10-24

Family

ID=37950917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105392A AR056838A1 (es) 2005-12-08 2006-12-06 Derivados de 1,2,5-tiadiazol

Country Status (26)

Country Link
US (1) US7700633B2 (es)
EP (1) EP1963292B1 (es)
JP (1) JP2009519248A (es)
KR (1) KR20080074969A (es)
CN (1) CN101326173A (es)
AR (1) AR056838A1 (es)
AT (1) ATE546440T1 (es)
AU (1) AU2006321905B2 (es)
BR (1) BRPI0619600A2 (es)
CA (1) CA2629857A1 (es)
CR (1) CR10049A (es)
EC (1) ECSP088506A (es)
ES (1) ES2381280T3 (es)
IL (1) IL191549A0 (es)
MA (1) MA30202B1 (es)
NO (1) NO20083031L (es)
NZ (1) NZ568243A (es)
PE (2) PE20071031A1 (es)
PL (1) PL1963292T3 (es)
PT (1) PT1963292E (es)
RU (1) RU2008127254A (es)
TN (1) TNSN08249A1 (es)
TW (1) TW200732315A (es)
UA (1) UA94724C2 (es)
WO (1) WO2007067615A2 (es)
ZA (1) ZA200804074B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
CA2629819A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
RU2008127253A (ru) * 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
WO2008067527A1 (en) * 2006-12-01 2008-06-05 Novartis Ag Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (es) * 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2020127924A1 (en) * 2018-12-21 2020-06-25 Bionice, S.L.U. Process and intermediates for the preparation of voxelotor
AU2020234712A1 (en) * 2019-03-14 2021-09-09 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
CA3162364A1 (en) * 2019-12-20 2021-06-24 Gesine Kerstin Veits Protein tyrosine phosphatase degraders and methods of use thereof
JP2024509962A (ja) * 2021-03-11 2024-03-05 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環及びその使用
CA3236854A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
TW202342437A (zh) * 2022-02-02 2023-11-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150535A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL372848A1 (en) * 2002-04-03 2005-08-08 Novartis Ag 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
DE60327811D1 (de) * 2002-12-30 2009-07-09 Vertex Pharma Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
CA2629819A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
RU2008127253A (ru) * 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
JP2009532379A (ja) * 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤

Also Published As

Publication number Publication date
JP2009519248A (ja) 2009-05-14
TW200732315A (en) 2007-09-01
KR20080074969A (ko) 2008-08-13
PL1963292T3 (pl) 2012-07-31
PE20100733A1 (es) 2010-10-29
MA30202B1 (fr) 2009-02-02
BRPI0619600A2 (pt) 2011-10-11
ATE546440T1 (de) 2012-03-15
CN101326173A (zh) 2008-12-17
NZ568243A (en) 2011-07-29
CR10049A (es) 2008-08-25
US20080262050A1 (en) 2008-10-23
TNSN08249A1 (en) 2009-10-30
EP1963292A2 (en) 2008-09-03
US7700633B2 (en) 2010-04-20
UA94724C2 (en) 2011-06-10
ES2381280T3 (es) 2012-05-24
WO2007067615A3 (en) 2007-11-15
AU2006321905A1 (en) 2007-06-14
EP1963292B1 (en) 2012-02-22
PE20071031A1 (es) 2007-11-15
ECSP088506A (es) 2008-07-30
AU2006321905B2 (en) 2011-08-11
PT1963292E (pt) 2012-05-10
ZA200804074B (en) 2009-03-25
CA2629857A1 (en) 2007-06-14
RU2008127254A (ru) 2010-01-20
NO20083031L (no) 2008-08-28
IL191549A0 (en) 2008-12-29
WO2007067615A2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
AR056838A1 (es) Derivados de 1,2,5-tiadiazol
AR056548A1 (es) Derivados de sulfonamidas, composiciones farmaceuticas y sus usos
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR056109A1 (es) Derivados de tiazolopiridina como activadores de la actividad de glucoquinasa
AR067562A1 (es) Compuestos heterociclicos inhibidores de kinasa
AR061651A1 (es) Analogos de piridina ii
AR048820A1 (es) Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3)
AR035517A1 (es) Derivados de piperazina, proceso para prepararlos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la elaboracion de medicamentos
AR048413A1 (es) Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR069078A1 (es) Derivados de piridina y pirazina
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR035518A1 (es) Derivados de carboxamida, un procedimiento para su preparacion, un medicamento que los contiene, el u so de los mismos para preparar un medicamento, y un conjunto (kit) que los incluye
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR051753A1 (es) Metodos para preparar compuestos de indazol
AR040352A1 (es) Derivados de indolinfenilsulfonamida
AR048241A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR064459A1 (es) Derivados de sulfonamida
AR066169A1 (es) Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR055959A1 (es) Derivados espiro para la modulacion de actividad de crth2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal